Evidence map›Paper›PMID 25970596›Full record

ArticlePloS one2015

Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis.

Teemu Mäntylä, Outi Mantere, Tuukka T Raij, Tuula Kieseppä, Hanna Laitinen, Jaana Leiviskä, Minna Torniainen, Lauri Tuominen, Outi Vaarala, Jaana Suvisaari

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Teemu MäntyläMental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Brain Research Unit, O.V. Lounasmaa Laboratory and Advanced Magnetic Imaging Centre, Aalto NeuroImaging, Aalto University School of Science, Espoo, Finland; Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland.
Outi MantereMental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland; Institute of Clinical Medicine, Department of Psychiatry, Helsinki University, Helsinki, Finland.
Tuukka T RaijBrain Research Unit, O.V. Lounasmaa Laboratory and Advanced Magnetic Imaging Centre, Aalto NeuroImaging, Aalto University School of Science, Espoo, Finland; Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.
Tuula KieseppäMental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.
Hanna LaitinenVaccination Programme Unit, National Institute for Health and Welfare, Helsinki, Finland.
Jaana LeiviskäGenomics and Biomarkers Unit, National Institute for Health and Welfare, Helsinki, Finland.
Minna TorniainenMental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lauri TuominenTurku PET centre, University of Turku, Turku, Finland; Department of Psychiatry, University of Turku, Turku, Finland.
Outi VaaralaRespiratory, Inflammatory and Autoimmunity, Innovative Medicine, AstraZeneca R & D, Mölndal, Sweden; Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland.
Jaana SuvisaariMental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
Finnish Institute for Health and Welfare · FIAalto University · FIHelsinki University Hospital · FIUniversity of Helsinki · FIUniversity of Turku · FI

Funding

X-RAY COMPATIBLE RF-COIL FOR MR IMAGINGP41RR009784 · NCRR · STANFORD UNIVERSITY · PI GLOVER, GARY H · 1995 to 2011
$15.0M
NCRR NIH HHS P41 RR009784NCRR NIH HHS P41 RR09784
6 · The paper itself

Abstract

First-episode psychosis (FEP) is associated with inflammatory and brain structural changes, but few studies have investigated whether systemic inflammation associates with brain structural changes in FEP. Thirty-seven FEP patients (median 27 days on antipsychotic medication), and 19 matched controls were recruited. Serum levels of 38 chemokines and cytokines, and cardiovascular risk markers were measured at baseline and 2 months later. We collected T1- and diffusion-weighted MRIs with a 3 T scanner from the patients at baseline. We analyzed the association of psychosis-related inflammatory markers with gray and white matter (WM) volume using voxel-based morphometry and WM diffusion using tract-based spatial statistics with whole-brain and region-of-interest (ROI) analyses. FEP patients had higher CCL22 and lower TGFα, CXCL1, CCL7, IFN-α2 and ApoA-I than controls. CCL22 decreased significantly between baseline and 2 months in patients but was still higher than in controls. The association between inflammatory markers and FEP remained significant after adjusting for age, sex, smoking and BMI. We did not observe a correlation of inflammatory markers with any symptoms or duration of antipsychotic treatment. Baseline CCL22 levels correlated negatively with WM volume and positively with mean diffusivity and radial diffusivity bilaterally in the frontal lobes in ROI analyses. Decreased serum level of ApoA-I was associated with smaller volume of the medial temporal WM. In whole-brain analyses, CCL22 correlated positively with mean diffusivity and radial diffusivity, and CXCL1 associated negatively with fractional anisotropy and positively with mean diffusivity and radial diffusivity in several brain regions. This is the first report to demonstrate an association between circulating chemokine levels and WM in FEP patients. Interestingly, CCL22 has been previously implicated in autoimmune diseases associated with WM pathology. The results suggest that an altered activation of innate immunity may contribute to WM damage in psychotic disorders.

Indexed as

Immunity, InnateAdolescentAdultAnisotropyAntipsychotic AgentsApolipoprotein A-ICase-Control StudiesChemokine CCL22Chemokine CCL7Chemokine CXCL1Diffusion Magnetic Resonance ImagingDiffusion Tensor ImagingFemaleFrontal LobeGene ExpressionGray MatterAntipsychotic AgentsApolipoprotein A-ICCL22 protein, humanCCL7 protein, humanChemokine CCL22Chemokine CCL7Chemokine CXCL1CXCL1 protein, humanInterferon-alphaTransforming Growth Factor alpha

Identifiers

PMID25970596
PMCPMC4430522
OpenAlexW1507038989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.